These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31633052)

  • 1. Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose.
    Fang W; McMahon LP; Bloom S; Garg M
    JGH Open; 2019 Oct; 3(5):438-440. PubMed ID: 31633052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypophosphatemia following the administration of intravenous iron formulations: A case report and literature review].
    Lecoq AL; Dong C; Carbonnel F; Becquemont L
    Therapie; 2021; 76(6):705-714. PubMed ID: 33962799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
    Schaefer B; Zoller H; Wolf M
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1009-1019. PubMed ID: 34850000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.
    Vilaca T; Velmurugan N; Smith C; Abrahamsen B; Eastell R
    J Bone Miner Res; 2022 Jun; 37(6):1188-1199. PubMed ID: 35426179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rare case of parental iron-induced persistent hypophosphatemia.
    Sullivan A; Lanham T; Rubin A
    J Community Hosp Intern Med Perspect; 2020 May; 10(2):166-167. PubMed ID: 32850057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management.
    Schaefer B; Tobiasch M; Wagner S; Glodny B; Tilg H; Wolf M; Zoller H
    Bone; 2022 Jan; 154():116202. PubMed ID: 34534708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron-induced hypophosphatemia: an emerging complication.
    Zoller H; Schaefer B; Glodny B
    Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):266-275. PubMed ID: 28399017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.
    Boots JMM; Quax RAM
    Drug Saf; 2022 Oct; 45(10):1019-1036. PubMed ID: 36068430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe osteomalacia with multiple insufficiency fractures secondary to intravenous iron therapy in a patient with Rendu-Osler-Weber syndrome.
    Callejas-Moraga EL; Casado E; Gomez-Nuñez M; Caresia-Aroztegui AP
    Bone Rep; 2020 Dec; 13():100712. PubMed ID: 32923530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome.
    Glaspy JA; Wolf M; Strauss WE
    Adv Ther; 2021 Jul; 38(7):3531-3549. PubMed ID: 34053011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteomalacia and Insufficiency Fractures Secondary to Intravenous Iron Therapy: A Case Report.
    Tozzi D; Tozzi J
    J Orthop Case Rep; 2020; 10(1):4-7. PubMed ID: 32547968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteomalacia following intravenous iron suppletion].
    Koks N; Donga E; Appelman-Dijkstra NM
    Ned Tijdschr Geneeskd; 2021 Oct; 165():. PubMed ID: 34854600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypophosphatemic osteomalacia induced by intravenous iron therapy: a case report.
    Samões B; Silva B; Martins A; Oliveira D; Rajão Martins F; Fonseca D; Costa L; Bernardes M
    Joint Bone Spine; 2023 Sep; 90(5):105586. PubMed ID: 37127260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study.
    Schoeb M; Räss A; Frei N; Aczél S; Brändle M; Bilz S
    Obes Surg; 2020 Jul; 30(7):2659-2666. PubMed ID: 32221822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypophosphatemia after injectable iron treatments in adults: Comparison between ferric carboxymaltose and iron sucrose].
    Grino M; Rigaux M; Lagarde AV; Robert V; Papailhau C; Vincentelli MB
    Ann Pharm Fr; 2023 Sep; 81(5):790-800. PubMed ID: 36963655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Risk of Hypophosphatemia Following the Administration of Intravenous Iron Formulations: A Network Meta-Analysis.
    Bellos I; Frountzas M; Pergialiotis V
    Transfus Med Rev; 2020 Jul; 34(3):188-194. PubMed ID: 32819760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe Hypophosphatemia Occurring After Repeated Exposure to a Parenteral Iron Formulation.
    Haridas K; Yau A
    Case Rep Endocrinol; 2022; 2022():1011401. PubMed ID: 36248222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Hypophosphatemia Following Ferric Carboxymaltose in a Patient With Inflammatory Bowel Disease.
    Ali A; Elmdaah A; Mustafa AM; Kumaravel Kanagavelu AS; Mohamed N; Sayed S
    Cureus; 2021 Dec; 13(12):e20452. PubMed ID: 35047286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.